Cubist Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 75   

Articles published

CBST 62.58 -3.12 (-4.75%)
price chart
Analyst Update: EMC Corporation, Teva Pharmaceutical Industries Ltd (ADR ...
Meanwhile, among the equities in focus are tech issue EMC Corporation (NYSE:EMC), as well as drug makers Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Cubist Pharmaceuticals Inc (NASDAQ:CBST), which have all attracted analyst ...
Related articles »  
Cubist Pharmaceuticals Inc.: Cubist Reports Second Quarter 2014 Financial ...
LEXINGTON, Mass.--(BUSINESS WIRE)-- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced results for the second quarter ended June 30, 2014.
Cubist Reports Second Quarter 2014 Financial Results  Wall Street Journal
Cubist strikes agreement with competitor to delay generic Cubicin  Boston Business Journal (blog)
Related articles »  
Cubist Pharmaceuticals (CBST) Scheduled to Post Earnings on Tuesday
Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in ...
Cubist Pharma. Q2 Profit Rises
On average, 13 analysts polled by Thomson Reuters expected the company to report a profit of $0.02 per share for the quarter.
Cubist Pharmaceuticals Q2 14 Earnings Conference Call At 5:00 PM ET
Cubist Pharmaceuticals Q2 14 Earnings Conference Call At 5:00 PM ET. By RTT News, July 22, 2014, 03:00:00 PM EDT. A A A. Vote up. loading.
Cubist Pharmaceuticals (CBST), Durata Therapeutics, Inc. (DRTX) PT Raised at ...
BofA/Merrill Lynch analyst Steve Byrne raised his price target on Buy-rated Cubist Pharmaceuticals (NASDAQ: CBST) to $89.00 (from $84.00) after the company announced approval for Sivextro in skin infections caused by MRSA. In the same report, the ...
Cubist Pharmaceuticals Receives New Coverage from Analysts at Gabelli (CBST)
Cubist Pharmaceuticals Inc logo Stock analysts at Gabelli started coverage on shares of Cubist Pharmaceuticals (NASDAQ:CBST) in a report issued on Friday.
Related articles »  
Cubist Pharmaceuticals's Buy Rating Reaffirmed at Jefferies Group (CBST)
Cubist Pharmaceuticals Inc logo Cubist Pharmaceuticals (NASDAQ:CBST)'s stock had its �buy� rating reaffirmed by research analysts at Jefferies Group in a report released on Monday.
Cubist Pharmaceuticals's "Positive" Rating Reaffirmed at Aegis (CBST)
Cubist Pharmaceuticals Inc logo Cubist Pharmaceuticals (NASDAQ:CBST)'s stock had its �positive� rating reiterated by equities researchers at Aegis in a research report issued on Monday.
Premarket Bulls: Cubist Pharmaceuticals (NASDAQ:CBST), Spectrum ...
Cubist Pharmaceuticals Inc. (NASDAQ:CBST) antibacterial drug Sivextro was approved by the U.S. Food and Drug Administration Friday for treatment of adult acute bacterial skin and skin structure infections.